Macquarie Reaffirms Their Buy Rating on Santos Limited (STOSF)
Macquarie analyst Mark Wiseman maintained a Buy rating on Santos Limited (STOSF – Research Report) today and set a price target of A$8.50. The company's shares closed last Monday at $3.70.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Wiseman covers the Energy sector, focusing on stocks such as Ampol Limited, Santos Limited, and Amplitude Energy. According to TipRanks, Wiseman has an average return of -6.8% and a 33.73% success rate on recommended stocks.
In addition to Macquarie, Santos Limited also received a Buy from UBS's Tom Allen in a report issued on April 18. However, on April 8, Bernstein maintained a Hold rating on Santos Limited (Other OTC: STOSF).
Based on Santos Limited's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.71 billion and a net profit of $636 million. In comparison, last year the company earned a revenue of $2.97 billion and had a net profit of $790 million
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STOSF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Top Stocks to Buy With Less Than $30
Pfizer's deep product pipeline, cost-cutting efforts, and dividend make the stock attractive. Adyen's shares look expensive for all the right reasons, and it should still deliver strong returns. 10 stocks we like better than Pfizer › Though wealthy and successful investors garner much attention on Wall Street, equity markets are accessible to the average person. That's one of the great things about investing in stocks. Even with $30, it's possible to buy stock in top companies that are likely to perform well over the long run -- and we're not talking about fractional shares, either. Let's consider two stocks that are trading for less than $30 per share but are great picks for long-term investors: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y). Pfizer has experienced subpar performances over the past three years, primarily due to unimpressive financial results. The company isn't out of the woods, either. It's facing some important patent cliffs, including one for its anticoagulant Eliquis, which will lose exclusivity in the U.S. by the end of the decade. Even with these challenges, the sell-off Pfizer has experienced in recent years may have created a brilliant opportunity to purchase its shares on the dip. The stock's forward price-to-earnings (P/E) was recently 8.3, compared to the healthcare industry's average of 16.2. Some might argue that Pfizer still isn't attractive because its prospects don't look bright. But partly thanks to its success in the coronavirus space -- and its generating unprecedented revenue for a biopharma company -- it has significantly beefed up its pipeline in recent years. Pfizer is still at it. It recently licensed a promising investigational cancer drug from China-based 3SBio called SSGJ-707. This medicine is a bispecific antibody, an area of the cancer market that is catching fire, and the pharmaceutical giant wants a piece of it. Pfizer's oncology pipeline appears particularly robust, but it also boasts promising candidates in other areas. It has more than 100 programs in total, so the company should successfully replenish its portfolio. Meanwhile, Pfizer has successfully reduced its expenses and remains engaged in cost-cutting initiatives that will further boost the bottom line. There are other reasons to invest in the company, including its dividend. Pfizer's poor performance in recent years has pushed its current yield up to a juicy 7%, and the company has increased its payouts by 62% in the past decade. The stock might not recover overnight, but for about $26 per share, Pfizer is a top pick for long-term, income-oriented investors. Adyen is a fintech leader that offers payment processing, payment gateways, and risk management services on a single, integrated platform. It is especially appealing to multinational companies that would otherwise have to deal with different providers for each of those needs in different regions. Adyen's ecosystem significantly simplifies things for its clients. That's why it has attracted the business of some major corporations, including Spotify Technology, Uber Technologies, and Microsoft. That's also why Adyen's revenue remains strong. Last year, the Netherlands-based company reported about 2 billion euros in revenue (about $2.3 billion), up 23% year over year, on 1.3 trillion euros ($1.5 trillion) in processed volume, which grew 33% compared to the year-ago period. Net income was 925.2 million euros ($1.1 billion), up 32% compared to 2023. Adyen has performed extremely well over the past year, thanks to its excellent results. However, its shares are becoming expensive; the forward P/E is around 47. While that means the stock could be somewhat volatile in the short term, the company's long-term prospects look attractive due to its wide moat and the industry's direction. Adyen benefits from switching costs -- its clients can't easily switch payment providers without risking disruption to their day-to-day activities. Elsewhere, Adyen -- which has a well-established business in Europe -- has been making a push in regions such as North America. It has only begun to scratch the surface of its opportunities in the U.S., where, as it points out, it only has a single-digit market share. Adyen won over major clients in Europe because of its superior offerings. It should do the same in the U.S., a less mature market for the company, but a significant one since it remains the world's single largest economy in terms of gross domestic product. So you can expect the stock to continue delivering superior returns over the long term, even if it experiences some short-term volatility. As of this writing, Adyen's shares are trading for a little under $20 apiece. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Adyen, Microsoft, Pfizer, Spotify Technology, and Uber Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 Top Stocks to Buy With Less Than $30 was originally published by The Motley Fool Sign in to access your portfolio
Associated Press
an hour ago
- Associated Press
Organto Foods Announces C$1.0 M Private Placement Financing with a Strategic Investor
TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / June 18, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF) ('Organto' or the 'Company') today announced it plans to complete a non-brokered private placement of up to 4,000,000 units of the Company (the 'Units') at a price of $0.25 per Unit (the 'Private Placement'), with each Unit consisting of one Common Share in the capital of the Company (a 'Common Share') and one-half common share purchase warrant of the Company (a 'Warrant'). Each full Warrant shall entitle the holder thereof to acquire one Common Share (a' Warrant Share') at a price per Warrant Share of C$0.35 for a period of 18 months from the closing date of the Private Placement. 'We're very pleased with our operational performance, having realized first quarter sales growth of 193.5%, gross profit dollar growth of 298.1%, our lowest cash operating costs as a percentage of sales in our history and our first-ever positive EBITDA quarter. Our business has continued to accelerate through the second quarter, which is quite encouraging, and we believe is a reflection of the strong momentum in our business. These results are the direct outcome of the extensive restructuring and strategic realignment we've executed over the past 18 months, laying a solid foundation for sustained growth, stability, and a clear path to profitability. With our continued growth and improvement in our share price, we believe it is prudent to complete this Private Placement as we conservatively manage our balance sheet.' commented Steve Bromley, Chair and Chief Executive Officer. The Company may pay finders' fees in connection with the Private Placement. The net proceeds from the Private Placement will be used to fund general working capital. Certain directors and officers of the Company may acquire securities under the Private Placement. Any such participation would be considered to be a 'related party transaction' as defined under Multilateral Instrument 61-101 ('MI 61-101"). The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any units issued to or the consideration paid by such persons will exceed 25% of the Company's market capitalization. Completion of the Private Placement will be subject to the prior approval of the TSX Venture Exchange as well as all other requisite corporate, regulatory and security holder approvals, as applicable. Further, all securities issued pursuant to the Private Placement described above will be subject to a minimum hold period of four months and one day from their date of issuance. There can be no assurance that the Company will be successful in completing the Private Placement. ON BEHALF OF THE BOARD Steve Bromley Chairman and CEO For more information, contact: Investor Relations John Rathwell, Senior Vice President, Investor Relations & Corporate Development 647 629 0018 [email protected] ABOUT ORGANTO Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto's business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders. FORWARD LOOKING STATEMENTS This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the 'safe harbor' provisions of the US Private Securities Litigation Reform Act ('forward-looking statements'). In particular, and without limitation, this news release contains forward-looking statements respecting Organto's business model and markets; Organto's belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto's belief that the impact of restructuring and realignment efforts was a key driver of its first quarter results; and Organto's belief it is prudent to complete this Private Placement as the Company conservatively manages its balance sheet. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that the Company will be able to complete the Private Placement and obtain all regulatory and requisite approvals in a timely manner and on acceptable terms. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company's business, see the 'Risks and Uncertainties' and 'Forward-Looking Statements' sections of the Company's annual and interim management's discussion and analysis filings with the Canadian securities regulators, which are available under the Company's profile at Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. SOURCE: Organto Foods, Inc. press release
Business Upturn
10 hours ago
- Business Upturn
GivBux, Inc. Finalizes Agreement to Acquire Charter House Financial AU and Affirms Plans to Launch Gold-Backed Expansion Initiative
NEWPORT BEACH, Calif., June 17, 2025 (GLOBE NEWSWIRE) — GivBux, Inc. (OTC: GBUX), a publicly traded Super App and charitable giving platform, today announced it has finalized the agreement to acquire Charter House Financial AU. The transaction will be completed by July 13, 2025 provided definitive Share Exchange Agreement whereby GivBux acquired 100% of the issued and outstanding shares of Charter House Ltd. in exchange for shares of GivBux common stock. By partnering with GivBux, the Charter House plans to expand participation in gold-backed financial benefits through the GivBux Super App. By integrating Charter House with the GivBux platform, it will help broaden access to gold-backed benefits for users. The hope is that operating Charter House as a wholly owned subsidiary it will generate multiple revenue streams. The founder of Charter House previously, Anthony Capazze has over 25 years of experience in the gold markets and has played a key role in several large financial transactions. He brings experience in municipal and corporate finance, institutional banking, and executive leadership. Anthony Cappaze stated, 'It is a tremendous opportunity for Charter House Financial AU to join forces with the innovative team at GivBux and be part of the fintech revolution. Their shopping and giving platform could be the ideal vehicle to launch our business model, and I look forward to our potential success together. Based on current plans and market conditions, the Company could generate up to $200 million in revenue during its first full year of operations.' Through the acquisition of Charter House, GivBux is sharpening its strategic focus to deliver innovative solutions that bridge the gap between tangible assets and digital finance. By gaining access to Charter House's international networks and asset-backed infrastructure, GivBux is well-positioned to develop gold-backed offerings that enhance the stability, trust, and utility of its digital ecosystem. The companies plan to jointly develop a platform that merges the stability of precious metals with the convenience of mobile payments and rewards. As part of its refined strategic focus, GivBux announced that it will not proceed with the strategic investment announced on March 29, 2025, due to both parties at this time not being able to meet the terms of the agreement, more specifically the inability of the investor to transfer the investment at this time. As well, the previously announced $39 million acquisition of as outlined in a press release dated February 3, 2025 will also not be proceeding as the seller has not been able to satisfactorily complete the required due diligence. The decision reflects the Company's commitment to focusing resources on initiatives that provide the most significant long-term value to shareholders. 'Getting the Charter House transaction across the finish line by July 13th will provide us with a tremendous opportunity to build the GivBux brand,' said Umesh Tim Singh, president of GivBux, Inc. 'This acquisition enhances our vision of combining real-world value with digital utility. We are building the future of accessible commerce where consumers can transact with confidence backed by tangible assets.' GivBux continues to expand its footprint in the fintech and digital commerce space. The GivBux app, which enables users to shop and give back simultaneously, has seen steady user growth and merchant adoption throughout 2025. The Company remains committed to innovation and delivering high-impact solutions that empower both consumers and communities. About GivBux, Inc. The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly and easily at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed towards a charity of their choice, embodying GivBux Inc.'s commitment to 'give back.' The GivBux Super App is free to use and available now at Google Play Store (Android) and the Apple App Store (IOS). The GivBux Super App is constantly evolving and adding new enhancements and functionalities, including social networking, e-commerce, banking, messaging, food delivery and transportation. GivBux is forging a new path in ecommerce and charitable giving and aspires to build the largest community of givers, first in the United States and eventually worldwide. For more details and regular updates, visit Forward-Looking Statements This press release contains 'forward-looking statements.' Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by GivBux, Inc. in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. The Company intends that all statements included herein, including those referring to future revenues and earnings, be subject to the 'Safe Harbors' provision of the Private Securities Litigation Reform Act of 1995. Contact: Umesh Tim Singh, President Email: [email protected] Instagram: X (formerly Twitter):
